NasdaqGM - Nasdaq Real Time Price USD

CorMedix Inc. (CRMD)

Compare

7.67

+0.15

+(1.99%)

At close: April 17 at 4:00:02 PM EDT

7.66

-0.01

(-0.13%)

After hours: April 17 at 6:11:00 PM EDT

Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years

Some CorMedix Inc. ( NASDAQ:CRMD ) shareholders are probably rather concerned to see the share price fall 41% over the...

Simply Wall St. yesterday

CRMD
+1.99%
RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term

RBC Capital notes that CorMedix (CRMD) announced preliminary Q1 2025 revenues for DefenCath of $39M, with an increase to first half of 2025 revenue guidance now at $62M-$70M, from $50M-$60M, off strong orders through early-March. As previously anticipated, Q2 orders are to be lower than Q1, due to the timing of shipments between customers – though encouragingly, management believes utilization is likely to continue to trend up, anticipating a stronger second half of the year, RBC adds. This morn

TipRanks 9 days ago

CRMD
+1.99%
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

‒ Q1 2025 Unaudited Net Revenue of $39.0 million ‒ ‒ Expected Q1 Adjusted EBITDA above $22.5 million ‒ ‒ Q1 2025 Cash and Cash Equivalents of Approximately $77.5 million ‒ BERKELEY HEIGHTS, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited first quarter results and provides an update on its business

GlobeNewswire 10 days ago

CRMD
+1.99%
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the 24th Annual Needham Virtual Healthcare Conference, taking place virtually on April 7-10, 2025. 24th Annual Needham Virtual Healthcare Conference Date:Tuesday, April 8, 2025Time:2:15p.m. EDTFormat:Fireside ChatWebc

GlobeNewswire 16 days ago

CRMD
+1.99%
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value

Key Insights The considerable ownership by individual investors in CorMedix indicates that they collectively have a...

Simply Wall St. 22 days ago

CRMD
+1.99%
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ...

Cormedix Inc (CRMD) reports its first profitable quarter with strong revenue growth and strategic partnerships, despite challenges in price erosion and customer expansion.

GuruFocus.com 23 days ago

CRMD
+1.99%
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full year ended Decembe

GlobeNewswire 24 days ago

CRMD
+1.99%
CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Tuesday, March 25th @ 8:30am

GlobeNewswire last month

CRMD
+1.99%
Loss-Making CorMedix Inc. (NASDAQ:CRMD) Set To Breakeven

We feel now is a pretty good time to analyse CorMedix Inc.'s ( NASDAQ:CRMD ) business as it appears the company may be...

Simply Wall St. last month

CRMD
+1.99%
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. Indeed, CorMedix ( NASDAQ:CRMD ) stock...

Simply Wall St. 2 months ago

CRMD
+1.99%
CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces it has engaged with WSI PBG, a subsidiary of Golden State Medical Supply, to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs (VA) and other federal facilities. This collaboration aims to enhance access t

GlobeNewswire 2 months ago

CRMD
+1.99%
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

‒ Q4 2024 Unaudited Net Revenue of Approximately $31mm ‒ ‒ FY 2024 Unaudited Net Revenue of Approximately $43mm ‒ ‒ Expects Q4 Adjusted EBITDA to Exceed $12mm ‒ BERKELEY HEIGHTS, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announces its preliminary unaudited fourth quarter results and provides an update on its business. These inc

GlobeNewswire 3 months ago

CRMD
+1.99%
CorMedix price target raised to $12 from $11 at RBC Capital

RBC Capital raised the firm’s price target on CorMedix (CRMD) to $12 from $11 and keeps an Outperform rating on the shares. The company has had a productive 2024 with the launch of DefenCath ongoing, and the management has remained in execution mode, establishing commercial agreements with dialysis providers and operators, including the signing of a large dialysis organization, the analyst tells investors in a research note. As DefenCath’s launch matures, RBC sees signs of reduced ordering and l

TipRanks 3 months ago

CRMD
+1.99%
CorMedix Inc. Added to Nasdaq Biotechnology Index

BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). CorMedix’s addition to the NBI will become effective prior to the market open on Monday, December 23, 2024. The NBI is designed to track the performance of a set of securities liste

GlobeNewswire 3 months ago

CRMD
+1.99%
^NBI
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products

BERKELEY HEIGHTS, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services (CMS) and the Center for Medicare and Medicaid Innovation (CMMI) released important policy updates that will broaden the access of Medicar

GlobeNewswire 4 months ago

CRMD
+1.99%
CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma Symposium, taking place in New York City on Thursday, November 7, 2024. Truist Securities BioPharma SymposiumDate:Thursday, November 7, 2024Format:1x1 meetingsLocation:Lotte New York Pal

GlobeNewswire 5 months ago

CRMD
+1.99%
Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic

CorMedix Inc. ( NASDAQ:CRMD ) shareholders will have a reason to smile today, with the analysts making substantial...

Simply Wall St. 5 months ago

CRMD
+1.99%
While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate

It's been a soft week for CorMedix Inc. ( NASDAQ:CRMD ) shares, which are down 23%. But that doesn't detract from the...

Simply Wall St. 5 months ago

CRMD
+1.99%
Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses

Cormedix Inc (CRMD) reports robust revenue and strategic partnerships, but faces challenges with increased operating costs and revenue variability.

GuruFocus.com 5 months ago

CRMD
+1.99%
CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

‒ Q3 2024 Net Revenue of $11.5 million ‒ ‒ Commercializing DefenCath with Four of Top Five US Dialysis Providers ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter and nine months ended September 30, 20

GlobeNewswire 5 months ago

CRMD
+1.99%

Performance Overview

Return	CRMD	S&P 500 (^GSPC)
YTD	-5.31%	-10.18%
1-Year	+40.99%	+5.19%
3-Year	+54.64%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CorMedix Inc. (CRMD)

Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years

RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value

Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ...

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

Loss-Making CorMedix Inc. (NASDAQ:CRMD) Set To Breakeven

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update

CorMedix price target raised to $12 from $11 at RBC Capital

CorMedix Inc. Added to Nasdaq Biotechnology Index

CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products

CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium

Rainbows and Unicorns: CorMedix Inc. (NASDAQ:CRMD) Analysts Just Became A Lot More Optimistic

While shareholders of CorMedix (NASDAQ:CRMD) are in the black over 1 year, those who bought a week ago aren't so fortunate

Cormedix Inc (CRMD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses

CorMedix Inc. Reports Third Quarter and Nine Month 2024 Financial Results and Provides Business Update

Performance Overview